OPTIMISE-CKD Study_current Clinical Landscape in Spain
Launched by ASTRAZENECA · Sep 24, 2024
Trial Information
Current as of May 19, 2025
Recruiting
Keywords
ClinConnect Summary
The OPTIMISE-CKD study is looking into how common kidney disease is in Spain and how it affects patients. Researchers will review existing medical data to understand how kidney function is measured and to track heart and kidney problems in people with chronic kidney disease (CKD). They will also examine how many patients are receiving treatments that help protect their kidneys.
To participate in this study, you need to be at least 18 years old and have some signs of kidney issues. This could mean having a specific lab test result showing kidney damage or a history of kidney disease in your medical records. However, if you are on dialysis, have had a kidney transplant, or have certain severe conditions like type 1 diabetes, you won't be eligible. If you join, you can expect to contribute to important research that could improve care for people with kidney disease in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years as of study index date
- * With renal function measured as either of the following:
- • At least 1 UACR measure of ≥30 mg/g; OR
- • At least 2 eGFR measures taken ≥90 days apart, of which both eGFR is ≤75 ml/min/1.73m2 ; OR
- • registered with Chronic Kidney Disease (CKD) diagnosis in the medical history (without biochemical confirmation)
- Exclusion Criteria:
- • History of stage 5 CKD, dialysis, organ transplant, type 1 diabetes, or gestational diabetes on or before the start date of the observation period
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sevilla, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported